Literature DB >> 23797339

GRPR antagonists for prostate cancer--prospects and caveats.

Rafael Roesler, Gilberto Schwartsmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23797339     DOI： 10.1038/nrurol.2013.42-c1

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates.

Authors:  Marc Beer; Matteo Montani; Josefine Gerhardt; Peter J Wild; Thomas F Hany; Thomas Hermanns; Michael Müntener; Glen Kristiansen
Journal:  Prostate       Date:  2011-07-07       Impact factor: 4.104

2.  A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies.

Authors:  G Schwartsmann; L P DiLeone; M Horowitz; D Schunemann; A Cancella; A S Pereira; M Richter; F Souza; A Brondani da Rocha; F H Souza; P Pohlmann; G De Nucci
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

Review 3.  Neuroendocrine cells in prostate cancer.

Authors:  George P Amorino; Sarah J Parsons
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2004       Impact factor: 1.807

4.  Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer.

Authors:  Constantinos Constantinides; Andreas C Lazaris; Konstantinos N Haritopoulos; Dimitrios Pantazopoulos; Michalis Chrisofos; Aris Giannopoulos
Journal:  World J Urol       Date:  2003-07-05       Impact factor: 4.226

Review 5.  Targeting GRPR in urological cancers--from basic research to clinical application.

Authors:  Rosalba Mansi; Achim Fleischmann; Helmut R Mäcke; Jean C Reubi
Journal:  Nat Rev Urol       Date:  2013-03-19       Impact factor: 14.432

6.  Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.

Authors:  Marianne Schrader de Oliveira; Giovana Cechim; Elisandra Braganhol; Daniel Garcia Santos; Luise Meurer; Cláudio Galvão de Castro; Algemir Lunardi Brunetto; Gilberto Schwartsmann; Gilberto Schwarstmann; Ana Maria Oliveira Battastini; Guido Lenz; Rafael Roesler
Journal:  J Neurooncol       Date:  2009-01-08       Impact factor: 4.130

7.  Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.

Authors:  Joy C Yang; Joon-ha Ok; J Erik Busby; Alexander D Borowsky; Hsing-Jien Kung; Christopher P Evans
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.